ý

Coronary Artery Disease: Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy - Diabetes or Left Ventricular Systolic Dysfunction (LVEF

Percentage of patients aged 18 years and older with a diagnosis of coronary artery disease seen within a 12-month period who also have diabetes OR a current or prior Left Ventricular Ejection Fraction (LVEF) < 40% who were prescribed ACE inhibitor or ARB therapy.

Date Reviewed: May 9, 2024
Do Not Support: Not Tested
    Group/Practice
Support
    Individual Clinician

Measure Info

MIPS 118 CBE 0066
Measure Type
Process
Measure Steward
American College of Cardiology
Clinical Topic Area
Diabetes
Care Setting
Outpatient
Data Source
Claims
Registry

ACP supports “Coronary Artery Disease: Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy - Diabetes or Left Ventricular Systolic Dysfunction (LVEF < 40%)” at the individual physician level. There is sufficient evidence to support the use of ACE inhibitors and ARB therapy in patients. However, new guidelines suggest that sacubitril/valsartan, an angiotensin receptor/neprilysin inhibitor (ARNI), should be the only pharmacotherapy used if at all possible. There are also some concerns about the two different populations in this performance measure: people with 1) CAD and LVSD and people with 2) CAD and diabetes. There should also be exception criteria for cost-prohibitive factors concerning medications. ACP does not support this measure at the group practice level since there is no testing data.